Comment on "Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases".

Yu, Tianfei; Yang, Changfei; Li, Ming

Yu, Tianfei; Yang, Changfei; Li, Ming.

Afiliação

Yu T; Department of Biotechnology, College of Life Science and Agriculture Forestry, Qiqihar University, Qiqihar, 161006, China. yutianfei2001@163.com.
Yang C; Department of Biotechnology, College of Life Science and Agriculture Forestry, Qiqihar University, Qiqihar, 161006, China.
Li M; Department of Computer Science and Technology, College of Computer and Control Engineering, Qiqihar University, Qiqihar, 161006, China. fionalee629@163.com.

Br J Cancer ; 130(6): 893-894, 2024 Apr.

Article em En | MEDLINE | ID: mdl-38378876

Assuntos

Neoplasias da Mama; Terapia Neoadjuvante; Humanos; Feminino; Prognóstico; Neoplasias da Mama/tratamento farmacológico; Trastuzumab/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google